1204 related articles for article (PubMed ID: 29196988)
1. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
2. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
6. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
7. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
8. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.
Qian J; Xue X; Shannon J
J Manag Care Spec Pharm; 2022 Sep; 28(9):1046-1052. PubMed ID: 36001100
[No Abstract] [Full Text] [Related]
11. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.
Pan C; Cao M; Yan C; Ou X; Zhang X; Xu W; Xu Y; Cui X
Expert Opin Drug Saf; 2023; 22(6):469-476. PubMed ID: 36794347
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
13. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
15. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
16. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
Semin Arthritis Rheum; 2024 May; 67():152461. PubMed ID: 38772185
[TBL] [Abstract][Full Text] [Related]
17. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
[TBL] [Abstract][Full Text] [Related]
19. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
20. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
